Evidence map›Paper›PMID 35895834›Full record

ArticleScience translational medicine2022

Antibody-mediated prevention of vaginal HIV transmission is dictated by IgG subclass in humanized mice.

Jacqueline M Brady, Meredith Phelps, Scott W MacDonald, Evan C Lam, Adam Nitido, Dylan Parsons, Christine L Boutros, Cailin E Deal, Wilfredo F Garcia-Beltran, Serah Tanno and 4 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Jacqueline M BradyRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02139, USA.ORCID 0000-0003-1762-6838
Meredith PhelpsRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02139, USA.ORCID 0000-0003-3522-4226
Scott W MacDonaldRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02139, USA.ORCID 0000-0002-0110-4026
Evan C LamRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02139, USA.ORCID 0000-0002-5556-2559
Adam NitidoRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02139, USA.ORCID 0000-0001-5679-838X
Dylan ParsonsRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02139, USA.ORCID 0000-0002-6026-4302
Christine L BoutrosRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02139, USA.
Cailin E DealRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02139, USA.
Wilfredo F Garcia-BeltranRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02139, USA.
Serah TannoRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02139, USA.ORCID 0000-0002-7278-1075
Harini NatarajanDepartment of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Dartmouth College, Hanover, NH 03755, USA.ORCID 0000-0002-9205-289X
Margaret E AckermanDepartment of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Dartmouth College, Hanover, NH 03755, USA.ORCID 0000-0002-4253-3476
Vladimir D VrbanacRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02139, USA.
Alejandro B BalazsRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02139, USA.ORCID 0000-0002-1767-3944
Ragon Institute of MGH, MIT and Harvard · USHarvard University · USDartmouth College · US

Funding

Engineering Humoral Immunity to Functionally Cure HIV InfectionDP2DA040254 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI BALAZS, ALEJANDRO BENJAMIN · 2015 to 2015
$2.6M
Directing Antibody Effector Activity via Controlled IgG Subclass SwitchingR01AI131975 · NIAID · DARTMOUTH COLLEGE · PI ACKERMAN, MARGARET E · 2017 to 2020
$2.6M
Development of Vectored ImmunoProphylaxis as a strategy against HIVK22AI102769 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI BALAZS, ALEJANDRO BENJAMIN · 2014 to 2015
$264k
The role of Fc function in broadly neutralizing antibody efficacy against HIVF31AI131747 · NIAID · HARVARD MEDICAL SCHOOL · PI BRADY, JACQUELINE MARLENE · 2017 to 2019
$102k
NIAID NIH HHS F31 AI131747NIAID NIH HHS K22 AI102769NIAID NIH HHS R01 AI131975NIDA NIH HHS DP2 DA040254
6 · The paper itself

Abstract

HIV broadly neutralizing antibodies (bNAbs) are capable of both blocking viral entry and driving innate immune responses against HIV-infected cells through their Fc region. Vaccination or productive infection results in a polyclonal mixture of class-switched immunoglobulin G (IgG) antibodies composed of four subclasses, each encoding distinct Fc regions that differentially engage innate immune functions. Despite evidence that innate immunity contributes to protection, the relative contribution of individual IgG subclasses is unknown. Here, we used vectored immunoprophylaxis in humanized mice to interrogate the efficacy of individual IgG subclasses during prevention of vaginal HIV transmission by VRC07, a potent CD4-binding site-directed bNAb. We find that VRC07 IgG2, which lacks Fc-mediated functionality, exhibited substantially reduced protection in vivo relative to other subclasses. Low concentrations of highly functional VRC07 IgG1 yielded substantial protection against vaginal challenge, suggesting that interventions capable of eliciting modest titers of functional IgG subclasses may provide meaningful benefit against infection.

Indexed as

HIV InfectionsImmunoglobulin GAnimalsAntibodies, NeutralizingBroadly Neutralizing AntibodiesFemaleHIV AntibodiesMiceVaginaAntibodies, NeutralizingBroadly Neutralizing AntibodiesHIV AntibodiesImmunoglobulin G

Identifiers

PMID35895834
PMCPMC9507259
OpenAlexW4288052049

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.